Anlotinib Versus Sunitinib as First‐Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial

BACKGROUND. Anlotinib is a tyrosine kinase inhibitor inhibiting angiogenesis. This multicenter, randomized phase II trial aimed to investigate the efficacy and safety of anlotinib in comparison with sunitinib as first‐line treatment for patients with metastatic renal cell carcinoma (mRCC). MATERIALS...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncologist
Päätekijät: Zhou, Ai‐Ping, Bai, Yuxian, Song, Yan, Luo, Hong, Ren, Xiu‐Bao, Wang, Xiuwen, Shi, Benkang, Fu, Cheng, Cheng, Ying, Liu, Jiyan, Qin, Shukui, Li, Jun, Li, Hanzhong, Bai, Xianzhong, Ye, Dingwei, Wang, Jinwan, Ma, Jianhui
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley & Sons, Inc. 2019
Aiheet:
Genitourinary Cancer
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6693716/
https://ncbi.nlm.nih.gov/pubmed/30902918
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0839
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia